This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Regulation on Medical Devices | |
|---|---|
| Name | Regulation on Medical Devices |
| Jurisdiction | Global |
Regulation on Medical Devices
Regulation on Medical Devices governs the approval, marketing, use, and surveillance of medical devices across jurisdictions such as the United States, European Union, Japan, China, and India. It intersects with legislation, agencies, and international instruments including the Food and Drug Administration, the European Commission, the World Health Organization, the International Medical Device Regulators Forum, and the Codex Alimentarius Commission. These regimes balance patient safety, innovation incentives, and market access amid technological advances from firms like Medtronic, Siemens Healthineers, Johnson & Johnson, GE Healthcare, and Philips.
Regulatory definitions frame which products fall under oversight, distinguishing devices from pharmaceuticals, biologics, and software as a medical device through statutes such as the Federal Food, Drug, and Cosmetic Act, the Medical Device Regulation (EU) 2017/745, and guidance from the World Health Organization. Scope covers implants, diagnostic equipment, prosthetics, in vitro diagnostics, and emerging categories like mobile apps from companies like Apple Inc. and Google. Definitions reference clinical intended use, mechanism of action, and risk profiles recognized by bodies including the International Organization for Standardization, the International Electrotechnical Commission, and the International Medical Device Regulators Forum.
Jurisdictions adopt diverse frameworks: the United States relies on the Food and Drug Administration pathways including 510(k) and Premarket Approval, while the European Union implements conformity under Notified Bodies guided by the Medical Device Regulation (EU) 2017/745 and the In Vitro Diagnostic Regulation (EU) 2017/746. Japan administers approvals via the Pharmaceuticals and Medical Devices Agency and the Ministry of Health, Labour and Welfare, whereas China transitioned oversight to the National Medical Products Administration. Emerging markets like Brazil with Agência Nacional de Vigilância Sanitária, Russia with Roszdravnadzor, Australia with the Therapeutic Goods Administration, and Canada with Health Canada show harmonization efforts influenced by trade agreements such as the Trans-Pacific Partnership and institutions like the World Trade Organization.
Classification schemes stratify devices by risk class—Class I to Class III in many systems—guided by statutes and standards like ISO 13485 and the Global Harmonization Task Force principles later adopted by the International Medical Device Regulators Forum. Risk assessment integrates hazard analysis methods from ISO 14971, clinical evaluation frameworks such as those endorsed by the European Commission and the Food and Drug Administration, and post-market data streams analyzed with tools used by Centers for Medicare & Medicaid Services and academic centers like Johns Hopkins University Hospital for evidence synthesis.
Conformity assessment paths include self-declaration, third-party certification by Notified Bodies, and regulatory review such as the FDA’s Premarket Notification (510(k)), Premarket Approval (PMA), and De Novo pathways. Technical documentation requirements reference standards like IEC 60601 series and ISO 10993 for biocompatibility, while submissions involve clinical trial protocols approved by ethics committees affiliated with institutions such as The Lancet–publishing investigators and registries like ClinicalTrials.gov. Market entry often requires labeling, instructions for use, and Unique Device Identification systems aligned with the Global Medical Device Nomenclature.
Vigilance systems collect adverse event reports via mechanisms like the FDA’s Medical Device Reporting and the EU’s Eudamed database, supplemented by manufacturer trend reporting and recalls administered by agencies such as Health Canada and the Therapeutic Goods Administration. Post-market requirements include registries (e.g., joint registries involving Orthopaedic surgeons and hospitals like Mayo Clinic), periodic safety update reports, and field safety corrective actions coordinated with stakeholders such as patient advocacy organizations like PatientsLikeMe.
Quality systems rely on standards and audits, including ISO 13485 certification and guidance from accreditation bodies like International Accreditation Forum members and national conformity assessment bodies such as ANSI and BSI Group. Clinical evidence generation follows Good Clinical Practice as codified in guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and trial registration with entities like ClinicalTrials.gov; evidence synthesis appears in systematic reviews in journals such as The BMJ and The New England Journal of Medicine.
Enforcement tools include inspections, warning letters, fines, injunctions, product seizures, and criminal charges enforced by agencies like the Department of Justice in the United States or administrative sanctions by the European Commission and national competent authorities. High-profile enforcement actions have involved corporations such as Philips and Johnson & Johnson, while international cooperation on enforcement is promoted through forums like the Interpol medical device crime initiatives and bilateral agreements between regulators such as FDA–EMA collaboration.